Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Drugs in NCCN Guidelines | |||||
| Chemotherapy | NCT00426257; M06OVH-OVHIPEC | III | Carboplatin, HIPEC, Paclitaxel | Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy | Among patients with stage III OC, the addition of HIPEC to interval cytoreductive surgery resulted in longer RFS and OS than surgery alone and did not show higher rates of side effects CarboPt+Pac+HIPEC vs CarboPt+Pac+Placebo: RFS: 14.2 vs 10.7 months* pub 2018 |
| Drugs in Clinical Development | |||||
| Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR | NCT01579812 | II | Carboplatin, Metformin, Paclitaxel | A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Metformin treatment before surgery and added to first-line chemotherapy is well tolerated and is associated with a better than expected OS, particularly in patients with stage II-III disease PFS: 18.0 months pub 2020 |
| Cell Cycle Inhibitors: CDK4/6 | NCT03531645 | II | Abemaciclib, Fulvestrant | A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | Neoadjuvant treatment with fulvestrant and abemaciclib is tolerable and demonstrates unprecedented response and complete gross resection rates in Low Grade Serous OC ORR: 60% (n=15) 7 patients w/ IDS: |
| Immunotherapy: Checkpoint Inhibitors/PD-1 | NCT03245892 | I | Carboplatin, Nivolumab, Paclitaxel | A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | In high-risk OC patients, addition of nivolumab to neoadjuvant chemotherapy and as maintenance shows promising PFS and favorable changes in the tumor microenvironment 90% achieved optimal cytoreducation at IDS abs Mar 2020 |
| Immunotherapy: Checkpoint Inhibitors/PD-L1 | NCT02726997 | I/II | Carboplatin, Durvalumab, Paclitaxel | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy 83% obtained optimal cytoreduction at surgery abs Apr 2020 |
| Immunotherapy: Immune Cell Stimulators/IL-12R | NCT02480374; OVATION 1 | I | Carboplatin, GEN-1, Paclitaxel | A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Adding GEN-1 IP to carboplatin+paclitaxel is safe, appears to be active in patients receiving neoadjuvant treatment and impacts the tumor microenvironment ORR at IDS: 85.7% (n=14) pub 2021 |
First-line treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Chemotherapy | |||||
| Chemotherapy | GOG-158 | III | Carboplatin, Cisplatin, Paclitaxel | Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. | No PFS or OS difference between cisplatin+paclitaxel and carboplatin+paclitaxel in optimally debulked stage III patients CisPt+Pac vs CarboPt+Pac: PFS: 19.4 vs 20.7 months pub 2003 |
| Drugs in NCCN Guidelines | |||||
| Chemotherapy | GOG-172 | III | Cisplatin, Paclitaxel | Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). | PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe side effects CisPt+Pac (IV) vs CisPt+Pac (IP): PFS: 18.3 vs 23.8 months* pub 2006 |
| Chemotherapy | NCT00003998; SCOTROC | III | Carboplatin, Docetaxel, Paclitaxel | A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer | Carboplatin+docetaxel is similar to carboplatin+paclitaxel in terms of response rates and PFS and OS CarboPt+Pac vs CarboPt+Doc: ORR: 59.5 vs 58.7% pub 2014 |
| Chemotherapy | NCT00326456; MITO-2 | III | Carboplatin, Liposomal doxorubicin, Paclitaxel | Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer | No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles CarboPt+Pac vs CarboPt+PLD: PFS: 16.8 vs 19.0 months pub 2011 |
| Chemotherapy | NCT01654146; ICON8 | III | Carboplatin, Paclitaxel | An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ICON8) | No significantly improved PFS with weekly dose-dense chemotherapy compared to standard chemotherapy every 3 weeks SoC vs CarboPt q3w+Pac qw vs CarboPt+Pac qw: PFS: 25 vs 25.8 vs 25.9 months pub 2019, pub 2021, pub 2022 |
| Drugs in Clinical Development | |||||
| Hormonal Therapy: Aromatase | Retrospective Study: Adjuvant Hormone Therapy in LGSC | Two sites | Letrozole, Tamoxifen, Anastrozole | Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival? | Promising PFS and OS in Low Grade Serous Cancer patients treated with letrozole, anastrozole, or tamoxifen following cytoreductive surgery PFS: Not Reached (41 months follow up) Pub 2017 |
| Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR | IRCT2016- 022726788N1 | II | Carboplatin, Metformin, Paclitaxel | Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers | Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients CarboPt+Pac+Met vs CarboPt+Pac: RFS: 48.0 vs 25.7 months pub 2018 |
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| Angiogenesis Inhibitors: VEGF | NCT00262847; GOG-218 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218) | Improved PFS, but no OS difference with addition of bevacizumab to carboplatin+paclitaxel; potential benefit for patients with stage IV disease CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac: All: Stage IV patients: pub 2019 |
| Angiogenesis Inhibitors: VEGF | NCT00483782; ICON7 | III | Carboplatin, Paclitaxel, Bevacizumab | ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer | Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac: All: pub 2011; 2015 |
| Angiogenesis Inhibitors: VEGF | NCT01462890; AGO-OVAR17 | III | Bevacizumab, Carboplatin, Paclitaxel | A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Longer treatment with bevacizumab for up to 30 months improves neither PFS nor OS in patients with newly diagnosed ovarian cancer. Therefore bevacizumab treatment duration of 15 months remains standard of care PFS: 24.2 vs 26.0 months pub 2022 |
| Drugs in NCCN Guidelines | |||||
| Chemotherapy | NCT01081262; mEOC/GOG-241 | III | Capecitabine, Carboplatin, Oxaliplatin, Paclitaxel, Bevacizumab | A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) | No firm conclusion about best treatment options for mucinous ovarian cancer can be made, however, slight evidence suggests that oxaliplatin/capecitabine should be investigated further CarboPt+Pac+/-Bev vs Oxa+Cap+/-Bev: PFS: 16.4 vs 14.2 months Bev vs no Bev: PFS: 18.1 vs 8.8 months pub 2017 |
| Drugs in Clinical Development | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT02470585; VELIA | III | Carboplatin, Paclitaxel, Veliparib | A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Veliparib added to chemotherapy and continued as maintenance significantly extends PFS in all newly diagnosed patients, but shows most benefit in BRCA MUT patients CarboPt+Pac+Vel w/Vel maint vs CarboPt+Pac+Vel vs CarboPt+Pac: All patients: pub 2019 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT00989651; GOG-9923 | I | Carboplatin, Cisplatin, Paclitaxel, Veliparib, Bevacizumab | A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Patients receiving IP cisplatin + IV/IP paclitaxel show promising PFS and OS when compared to patients receiving IV carboplatin+paclitaxel, however differences may be reflective of selection bias toward patients enrolled on the IP chemotherapy arm IV vs weekly IV vs IP (all w/ Vel cont): PFS: 24.5 vs 23.5 vs 43.2 months pub 2020, abs Mar 2020 |
| Angiogenesis Inhibitors: VEGF | NCT00951496; GOG-252 | III | Bevacizumab, Carboplatin, Cisplatin, Paclitaxel | A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Compared to the IV reference arm, PFS was not significantly increased with either IP regimen IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint: PFS: 24.9 vs 27.4 vs 26.2 months stage II/III disease with no residual disease (R0): pub 2019, abs Mar 2022 |
| Immunotherapy: Checkpoint Inhibitors/PD-1 | NCT02766582 | II | Carboplatin, Paclitaxel, Pembrolizumab | Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer | Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising 28 patients abs Mar 2020 |
| Immunotherapy: Checkpoint Inhibitors/PD-L1 | NCT02718417; JAVELIN Ovarian 100 | III | Avelumab, Carboplatin, Paclitaxel | A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/Or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 | Avelumab addition to carboplatin+paclitaxel and/or continued as maintenance therapy for newly diagnosed ovarian cancer patients does not improve PFS; PD-L1, CD8, and gBRCA1/2 status did not predict differential clinical benefit CarboPt+Pac+Ave+Ave maint vs CarboPt+Pac+Ave maint vs CarboPt+Pac: ORR: 36.0 vs 30.4 vs 30.4% pub 2021 |
| Immunotherapy: Checkpoint Inhibitors/PD-L1 | NCT03038100; IMagyn050 | III | Atezolizumab, Carboplatin, Paclitaxel, Bevacizumab | A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Atezolizumab does not significantly improve PFS in the ITT or PD-L1+ population. The combination is generally well tolerated with manageable AEs; neither BRCA MUT nor HRD+ was associated with greater clinical benefit from adding atezolizumab CarboPt+Tax+Bev+Ate vs CarboPt+Tax+Bev+Placebo: PD-L1+ patients: pub 2021 |
| Immunotherapy: Vaccine/TAA | NCT02107937; SOVO1 | II | DCVAC/OvCa | A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma | DCVAC/OvCa sequential to chemo is associated with a statistically significant improvement in PFS in patients undergoing first-line treatment DCVAC sequential to chemo vs chemo alone: pub 2022 |
| Immunotherapy: Antibodies/MUC16 (CA125) | NCT01616303 | II | Carboplatin, Oregovomab, Paclitaxel | Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma | Addition of oregovomab to carboplatin+paclitaxel and continued as maintenance treatment significantly increases PFS and OS CarboPt+Pac+Ore vs CarboPt+Pac: PFS: 41.8 vs 12.2 months* pub 2020 |